In focus · trending topic

FDA approved antibiotic

2 stories · following the connections

Melinta Therapeutics Signs $90 Million Financing Agreement with Oberland Capital to Fund Baxdela™ Commercial Activities and Expansion into Additional Indications

By Nasdaq OMXJun 29, 2017, 1:56 PM UTC

Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

By Nasdaq OMXJun 19, 2017, 8:30 PM UTC